THADA

Overview

THADA (Thyroid Adenoma Associated) is a gene frequently rearranged in benign thyroid adenomas and implicated in thyroid tumorigenesis. In the TCGA comprehensive genomic characterization of papillary thyroid carcinoma (PTC), THADA fusions were identified as recurrent driver alterations at low frequency.

Alterations observed in the corpus

  • THADA fusions detected in 6/484 (1.2%) papillary thyroid carcinomas (PTCs) in the TCGA PTC cohort; mutually exclusive with BRAF/RAS/EIF1AX point mutations and other fusions (Fisher’s exact p=4.9×10⁻⁴³ for all fusions vs. point mutations). PMID:25417114

Cancer types (linked)

  • THPA (Papillary Thyroid Carcinoma): THADA fusions occur in 1.2% of PTCs and are mutually exclusive with the dominant MAPK-pathway drivers, suggesting they represent an independent oncogenic mechanism. PMID:25417114

Co-occurrence and mutual exclusivity

  • THADA fusions are mutually exclusive with BRAFV600E, RAS mutations, EIF1AX mutations, and other gene fusions (RET, BRAF, PAX8/PPARG, ALK, NTRK) in PTC. PMID:25417114

Therapeutic relevance

  • No specific therapeutic targeting of THADA fusions has been described in the corpus. The mutual exclusivity with MAPK drivers suggests THADA-fusion PTCs may lack the BRAF/RAS-pathway vulnerabilities targeted by current kinase inhibitors.

Open questions

  • The specific fusion partners of THADA in PTC and their oncogenic mechanism have not been detailed in the extracted data.
  • Whether THADA fusions occur in other thyroid cancer subtypes (follicular, anaplastic) is not characterized in this corpus.

Sources

  • PMID:25417114 — TCGA integrated genomic characterization of 496 papillary thyroid carcinomas.

This page was processed by crosslinker on 2026-05-14.